Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b, Open-Label, Safety and Tolerability Study of TTAC-0001 in Combination With Pembrolizumab in Patients With Metastatic Triple-Negative Breast Cancer

Next Previous
Trial Profile

A Phase 1b, Open-Label, Safety and Tolerability Study of TTAC-0001 in Combination With Pembrolizumab in Patients With Metastatic Triple-Negative Breast Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 19 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Olinvacimab (Primary) ; Pembrolizumab (Primary)
  • Indications Advanced breast cancer; Carcinoma; Male breast cancer; Triple negative breast cancer
  • Focus Adverse reactions
  • Sponsors PharmAbcine

    • Most Recent Events

    • 15 Aug 2022 Planned End Date changed from 26 Feb 2022 to 26 Oct 2022.
    • 25 Feb 2022 According to a PharmAbcine media release, last patient last visit has been completed in the trial. The last patient, who just completed 35 cycles of olinvacimab and pembrolizumab combo treatment, will receive olinvacimab in monotherapy as compassionate use starting from early March 2022. In addition, another patient, who showed CR in the target lesion, has already been receiving olinvacimab as compassionate use since August 2021 and is in stable condition.
    • 09 Sep 2021 According to PharmAbcine media release, a Patent Cooperation Treaty (PCT) application was submitted jointly with Merck Sharp & Dohme for the combination therapy of olinvacimab, the Company anti-VEGFR2 antibody, and KEYTRUDA (pembrolizumab), MSDs anti-PD-1 antibody, for the treatment of cancer based on this trial
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top